Liberata Sportiello
Overview
Explore the profile of Liberata Sportiello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sportiello L, La Mantia G, Panzarella V, Colella G, Potenza S, Oteri G, et al.
Oral Dis
. 2024 Oct;
PMID: 39370676
Objectives: The aim of this study was to perform a descriptive analysis of oropharyngeal adverse events (AEs) related to drugs and/or vaccines in order to provide useful information for clinicians....
2.
Gaio M, Vastarella M, Sullo M, Scavone C, Riccardi C, Campitiello M, et al.
Pharmaceuticals (Basel)
. 2024 Jul;
17(7).
PMID: 39065754
Treatment for pregnant women with psoriasis is limited by the lack of information typically related to clinical trials. While anti-tumor necrosis factor (TNF) drugs offer therapeutic benefits, their safety during...
3.
Scavone C, Liguori V, Adungba O, Di Giulio Cesare D, Sullo M, Andreone V, et al.
Front Neurol
. 2024 Jul;
15:1386527.
PMID: 38957352
No abstract available.
4.
Mirra D, Esposito R, Spaziano G, Sportiello L, Panico F, Squillante A, et al.
Biomedicines
. 2024 May;
12(5).
PMID: 38791013
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is commonly considered to be a potent driver of non-small cell lung cancer (NSCLC) development and related mortality. A...
5.
Sportiello L, Capuano A
Front Pharmacol
. 2024 May;
15:1397291.
PMID: 38694914
No abstract available.
6.
Ruggiero R, Mascolo A, Spezzaferri A, Carpentieri C, Torella D, Sportiello L, et al.
Pharmaceuticals (Basel)
. 2024 Feb;
17(2).
PMID: 38399362
Background: A potential risk of suicide associated with liraglutide or semaglutide treatments has recently emerged. Therefore, we decided to investigate the reporting probability of suicidal events among glucagon-like peptide-1 receptor...
7.
Sportiello L, Di Napoli R, Balzano N, Mascolo A, Ruggiero R, Di Costanzo L, et al.
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004432
(1) Background: The purpose of study was to compare the safety profile of glatiramer with natalizumab, alemtuzumab and ocrelizumab in pregnant and lactating women affected by multiple sclerosis (MS). (2)...
8.
Bernardi F, Mascolo A, Sarno M, Capoluongo N, Trama U, Ruggiero R, et al.
Vaccines (Basel)
. 2023 Oct;
11(10).
PMID: 37896978
Introduction: Real-world safety studies can provide important evidence on the thromboembolic risk associated with COVID-19 vaccines, considering that millions of people have been already vaccinated against COVID-19. In this study,...
9.
Mascolo A, Di Napoli R, Balzano N, DAlessio E, Izzo I, Rossi F, et al.
Front Pharmacol
. 2023 Sep;
14:1229304.
PMID: 37654615
Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is authorized for the treatment of chronic lymphocytic leukemia (CLL). This study aims to explore the cardiac safety profile of ibrutinib in comparison...
10.
Mascolo A, Sportiello L, Rafaniello C, Donniacuo M, Ruggiero D, Scisciola L, et al.
Biomed Pharmacother
. 2023 May;
164:114912.
PMID: 37210896
Background: Despite the available evidence showing an association between cardiac arrhythmia and Immune Checkpoint Inhibitors (ICIs), few studies have compared this risk between ICIs. Objectives: We aim to evaluate Individual...